Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Cerebrospinal fluid (CSF) samples are increasingly being used for genomic profiling of brain tumors, offering a less invasive alternative to tissue biopsies. CSF samples provide a higher signal-to-noise ratio for detecting tumor-derived cell-free DNA (cfDNA) compared to plasma samples, making them particularly useful for …
February 2026—Rapid genome sequencing in neonatal intensive care units is a complex process involving a multidisciplinary team, including pathologists, genetic counselors, and clinicians. The goal is to identify genetic causes of complex medical conditions in newborns, often born prematurely with multiple health issues.
February 2026—A six-year-old boy presented with abdominal pain and was found to have a large mediastinal mass. Biopsy revealed a spindle cell sarcoma, and molecular testing identified an NTRK1 rearrangement, confirming the diagnosis of NTRK1-rearranged spindle cell sarcoma.
February 2026—This is the fourth in a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with representatives of a company to spotlight its laboratory solutions. He spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup.
Bringing next-generation sequencing (NGS) in-house can be approached in two ways: a rapid, comprehensive implementation or a gradual, progressive build. Florida Cancer Specialists opted for a rapid approach, starting with a complex pancancer solid tumor panel, which facilitated the addition of smaller assays.
The absence of CDC surveillance data due to the government shutdown has created uncertainty about the severity and impact of the current respiratory virus season. While regional public health surveillance provides some insights, concerns remain about the potential for a severe season, exacerbated by vaccine hesitancy and changes in vaccine guidance.
A 21-year-old male with a history of acute promyelocytic leukemia (APL) presented with symptoms suggestive of relapse. While standard tests like qRT-PCR and amplicon-based sequencing failed to detect the PML::RARA fusion, AMP NGS revealed an atypical bcr2 transcript with a novel breakpoint.
October 2025—Bringing equity to cystic fibrosis carrier and newborn screening was the aim of expert groups that have released their recommendations for both. Carrier screening for 23 CFTR variants, which had been the recommended practice since 2004, was working well, “but only if a person was of white European or Ashkenazi Jewish ancestry,” said Karen Raraigh, MGC, CGC, assistant professor of genetic medicine at Johns Hopkins University. “It wasn’t working all that well because it was not an equitable test.” For people of Asian American and African American ancestry, she said, the detection rate was lower.
October 2025—Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a mature B-cell neoplasm composed of small atypical lymphoid cells that often coexpress CD5 and CD23 and are characterized by scant cytoplasm, clumped nuclear chromatin, and indistinct nucleoli. CLL/SLL can involve the peripheral blood, bone marrow, and various lymphoid tissues such as the lymph nodes, tonsils, and spleen, and it may occasionally present in extranodal locations as well.1 Within involved lymph nodes, pale-staining proliferation centers consisting of prolymphocytes or paraimmunoblasts are a characteristic finding in CLL/SLL.
September 2025—The Food and Drug Administration’s efforts to regulate laboratory-developed tests as medical devices came to a decisive halt this spring with a ruling from the U.S. District Court …
